Organigram to buy Sanity Group in deal valuing German cannabis firm at up to €250M

What's the deal? OrganigramDealroom has a profile for this one. Try Dealroom → has agreed to acquire Germany’s Sanity Group in a deal valuing the company at up to €250 million. Already a 9% shareholder, Organigram will buy the remaining stake for roughly €227 million.

The consideration will be split between cash and Organigram shares, with €113.4 million paid upfront and up to €113.8 million tied to financial performance over the next two years.

Sanity operates in medical cannabis and consumer wellness products in Germany. Organigram said the deal will expand its international footprint and strengthen its base for European growth.

Why now? Germany’s cannabis reforms have increased medical access and opened the door to a regulated recreational market, making it the key battleground for European expansion.

For Organigram, the acquisition offers diversification beyond Canada’s crowded and slower-growing market.

What could go wrong? The earnout structure means much of the value depends on execution. Regulatory shifts in Europe and the challenge of integrating cross-border operations could also weigh on returns.

The signal: The deal signals rising confidence in Germany’s regulated cannabis market and a return of cross-border consolidation. Canadian producers are again looking abroad for growth as Europe’s framework matures.

Sources:
Sanity Group
Organigram
Business Wire
Business of Cannabis
Handelsblatt

J.V.